IONS
Ionis Pharmaceuticals, Inc.
$45.40
+2.30% 2026-10-20
Healthcare
IONSSPY
1W
+7.1%
1M
+2.2%
3M
-15.0%
6M
-39.3%
YTD
-42.6%
1Y
-38.3%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsSevere Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight
PR Newswire · 15h ago
Ionis Pharmaceuticals Receives Approval Recommendation for Tryngolza's Indication Expansion in EU
MT Newswires · Oct 16
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
Business Wire · Oct 16
Ionis Pharmaceuticals Shares Rise After UBS Upgrade
MT Newswires · Oct 15
UBS Upgrades Ionis Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $88 From $46
MT Newswires · Oct 15
Key stats
Market cap$7.5B
P/E (trailing)–
P/E (forward)-40.8
52-week range42.08 – 86.74
Revenue growth (YoY, latest qtr)-40.7%
Dividend yield0.00%
Analyst consensusBuy (23)
Mean price target$83.83 (+85%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
•Piotroski F-score4/9
▼Altman Z1.0 (distress)
▲Analyst target+85% (23 analysts)
Discounted cash flow
Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.38 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-1.11 vs trailing $-3.48. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
98.2%
Operating margin
-68.0%
FCF margin
-64.2%
Net margin
-64.7%
Return on equity
-128.5%
Return on invested capital
-323.2%
Net debt / EBITDA
–
Current ratio
7.9×
Interest cover
-31.6×
Cash conversion (OCF/NI)
–
Piotroski F-score 4/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 1.0 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$84
+85%
Analysts
23
Buy
Range
$54–$105
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $943.7M | $-381.4M | $-320.0M |
| 2024 | $705.1M | $-453.9M | $-546.2M |
| 2023 | $787.6M | $-366.3M | $-331.3M |
| 2022 | $587.4M | $-269.7M | $-290.1M |
| 2021 | $810.5M | $-28.6M | $18.8M |
| 2020 | $729.3M | $-444.3M | $772.0K |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +17.1%.
Earnings
Next report: 2026-11-04 · before open · EPS est -0.92
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | -0.88 | -0.42 | +51.7% |
| 2026-04-29 | -0.77 | -0.30 | +60.9% |
| 2026-02-25 | -1.22 | -1.15 | +5.6% |
| 2025-10-29 | -1.05 | -0.61 | +41.8% |
| 2025-07-30 | 0.16 | 0.85 | +415.1% |
| 2025-04-30 | -1.03 | -0.92 | +10.4% |
| 2025-02-19 | -0.84 | -0.43 | +49.0% |
| 2024-11-06 | -0.98 | -0.72 | +26.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $267.9M | -40.7% |
| 2026-03-31 | $246.1M | – |
| 2025-12-31 | $203.3M | – |
| 2025-09-30 | $156.7M | – |
| 2025-06-30 | $452.0M | – |
Analyst actions
UBS
PT $88
2026-10-15 · up
Neutral → BuyPT $88
HC Wainwright & Co.
PT $100
2026-09-24 · reit
Buy → BuyPT $100
JP Morgan
PT $70
2026-09-22 · main
Overweight → OverweightPT $70
Guggenheim
PT $80
2026-09-15 · main
Buy → BuyPT $80
Barclays
PT $85
2026-09-09 · main
Overweight → OverweightPT $85
Morgan Stanley
PT $104
2026-09-08 · main
Overweight → OverweightPT $104
Insider trades
Devers Shannon L.
$59.1K
EVP, Chief Human Resources Ofc · 2026-10-16
SELL$59.1K
Swayze Eric
$2.3K
EVP Research · 2026-10-16
SELL$2.3K
Hayden Michael R
$258.0K
Director · 2026-07-31
BUY$258.0K
Hayden Michael R
$800.7K
Director · 2026-07-30
BUY$800.7K
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:13:49 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.